In syngeneic CT26 tumor models, high-affinity PD-1 was successful in treating both small (50 mm3) and large tumors (150 mm3), whereas the action of the anti-PD-L1 antibody was eliminated against large tumors, which is consistent with these benefits. This evidence concerns the gene CD274 and neoplasm.